Originally produced by Yang Xixia, Jianshi Bureau, July 14, 2026 20:24 Beijing

On July 14, China’s innovative drug industry saw another major deal: ج Dizal Pharma willgrant AstraZeneca the exclusive global development and commercialization rights to suvolotinib. AstraZeneca will pay Dizal Pharma a $600 million upfront payment and $900 million in milestone payments, with clinical development and sales milestones capped at $400 million and $500 million, respectively.

Simply put, AstraZenecabought out suvolotinib outright for $1.5 billion.

As soon as the news broke, Dizal Pharma’s stock surged 20CM in the afternoon. The capital market recognized the certainty of this deal. Unlike other BD deals that often run into the billions of dollars, Dizhe’s $1.5 billion total may not be large, but the $600 million upfront payment is real cash in hand, and the future milestone payments are also highly certain. This is the fundamental reason the market is willing to pay up.

Suvolotinib is the world’s first oral small-molecule drug for treating rare EGFR exon 20 mutations in non-small cell lung cancer, and it has already been approved as a second-line therapy in both China and the United States; its originality speaks for itself. The application for first-line indications of suvolotinib has already been submitted in both China and the United States, and it will challenge Johnson & Johnson’s amivantamab.

AstraZeneca’s osimertinib is the “big brother” in the EGFR inhibitor field. The collaboration not only further deepens the relationship between Dizal Pharma and AstraZeneca, but also means that suvolotinib’s future clinical development and market promotion will have strong support. The completion of this transaction will not only deliver ample cash flow to Dizal Pharma, but also create robust safeguards for the future development of its product pipeline.

01
A two-way embrace between old partners

Dizal Pharmaceutical itself was founded in 2017 with investment from companies such as AstraZeneca. Its other commercialized product, golidocitinib, was also brought in from AstraZeneca as a preclinical compound, then developed in-house and advanced to market by itself. About 35% of Dizal Pharmaceutical’s management and R&D team came from AstraZeneca, and company chairman Zhang Xiaolin once led the development program for AstraZeneca’s flagship EGFR inhibitor osimertinib.

It could be said that across the entire pharmaceutical industry, AstraZeneca and Dizhe are the best pair, as each understands exactly what the other wants.

AstraZeneca’s osimertinib is the benchmark for third-generation EGFR inhibitors, but it is now under siege from multiple competitors; in China alone, there are at least nine third-generation EGFR inhibitors competing.

EGFR exon 20 mutation has always been a tough nut for AstraZeneca to crack. AstraZeneca once collaborated with CSPC Group, combining CSPC’s EGFR monoclonal antibody with osimertinib for the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations. On November 2023, CSPC Group disclosed that the two sides would conduct Phase III clinical trials, after which there were basically no further updates.

The EGFR exon 20 target is notoriously difficult to develop, and Takeda’s mobocertinib was also forced to be withdrawn from the market in 2023. To date, the only players still in the ring are sunvozertinib and Johnson & Johnson’s amivantamab. At present, sunvozertinib has the Chinese market to itself for second-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations. For the more critical first-line setting, sunvozertinib is currently behind amivantamab in both China and the U.S. and is still awaiting approval from regulators in both countries.

According to clinical data, when used as a first-line monotherapy for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations, sunvozertinib achieved a confirmed objective response rate of 58.9%, with the best ORR reaching 68.1%. Based on the data alone, sunvozertinib is slightly inferior to amivantamab’s combination therapy. But amivantamab is a combination regimen that requires chemotherapy drugs, whereas sunvozertinib is an oral monotherapy, giving it strong competitive advantages in safety and adherence.

With the deal in place, Dizal Pharmaceutical has gained the capital to go head-to-head with Johnson & Johnson in the future, while AstraZeneca has also made up for its regret in the treatment of non-small cell lung cancer.

02
Breaking into the international market is hard

The successful licensing of sunvozertinib is a very encouraging piece of news for the industry.

Since its launch, sunvozertinib has seen impressive uptake in the Chinese market. In 2025, sunvozertinib sales reached RMB 576 million, up 85.21% year over year. In the first quarter of 2026, Dizal Pharmaceutical’s sales revenue continued to grow rapidly, reaching 253 million yuan, up 58% year over year.

Dizal Pharmaceutical has always been tight-lipped about the performance of Surufatinib in overseas markets. By the end of 2025, the company had not disclosed any overseas revenue, which means that after receiving U.S. approval in early July 2025, Surufatinib had not yet been sold in significant volumes in the United States by the end of last year.

Dizhe’s decision this time to license the global rights to Surufatinib to AstraZeneca came as a complete surprise both inside and outside the industry. Although Dizal Pharmaceutical has still not achieved commercial profitability, with the steady sales of Surufatinib and Glumetinib, it is foreseeable that Dizal Pharmaceutical’s finances will move toward balance.

In addition, Surufatinib is also being explored for the treatment of non-small cell lung cancer with EGFR PACC mutations, a group that accounts for about 12.5% of EGFR-mutated non-small cell lung cancer cases. According to data disclosed by Dizal Pharmaceutical, Surufatinib monotherapy as a first-line treatment in advanced non-small cell lung cancer patients carrying EGFR PACC or other rare mutations achieved an objective response rate of 81.3% and a disease control rate of 100%.

The clinical value of Surufatinib is evident to all —what is lacking in the short term is commercialization capability. The upfront payment from AstraZeneca will greatly bolster Dizal Pharmaceutical’s cash flow; in the long run, AstraZeneca can maximize Surufatinib’s coverage and sales in overseas markets, a goal that would be difficult for Dizhe to achieve on its own.

This year, Chinese innovative drugs continue to maintain strong momentum in overseas licensing. The National Medical Products Administration disclosed that in the first half of this year, the total value of overseas licensing deals for Chinese innovative drugs reached $110 billion, equivalent to 80% of the total for all of 2025 and twice that of the year before last. In the surging wave of going global, what capital truly cares about is tangible returns. Surufatinib is a successful example of Chinese innovative drugs; turning certain results into certain returns is the key reason capital is willing to pay.

In China’s innovative drug industry, there are already many Chinese biotech + large MNC combinations, such as BeiGene with Amgen and Innovent with Eli Lilly. Deeply tying up with multinational pharmaceutical companies seems to mean a greater likelihood of incubating blockbuster products. Rather than letting its pipeline be buried, cooperation with AstraZeneca will give Dizhe a promising future.